Take a look at the therapies that have already reached the market.
Opthea discontinues COAST and ShORe sozinibercept combination therapy trials
Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis)
A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
Up for debate: Clinicians take on hot topics at the Congress on Controversies in Ophthalmology
This year, the COPHy meeting moves beyond retina, addressing uveitis, neuro-ophthalmology and glaucoma in Seville, Spain
International study illuminates economic burden of late-stage age-related macular degeneration
Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US